Literature DB >> 26671314

Multiple resections and survival of recurrent glioblastoma patients in the temozolomide era.

Alicia Ortega1, J Manuel Sarmiento1, Diana Ly1, Miriam Nuño1, Debraj Mukherjee1, Keith L Black1, Chirag G Patil2.   

Abstract

Glioblastoma (GBM) is the most prevalent and aggressive primary brain tumor in adults for which recurrence is inevitable and surgical resection is often recommended. We investigated the relationship between multiple tumor resections and overall survival (OS) in adult glioblastoma patients who received adjuvant radiotherapy and temozolomide following initial surgery. We retrospectively reviewed the records of all newly diagnosed adult GBM patients with tumor recurrence at our institution from March 2003 to October 2012. Kaplan-Meier survival estimates and multivariate analysis using Cox's proportional hazards model were utilized to evaluate the impact of multiple resections on OS. A total of 202 GBM patients were analyzed; 83 (41.1%), 94 (46.5%), and 25 (12.4%) patients underwent one, two, and three or more total resections, respectively. Patients who underwent multiple resections were significantly younger (p<0.0001) and had higher perioperative Karnofsky Performance Status scores (p<0.0001) than single resection patients. The median OS in months was 21.1, 25.5, and 29.0 for patients who had one, two, and three or more resections, respectively (Wilcoxon p=0.03). In a confounder-adjusted multivariate model, patients with multiple resections did not have significantly improved survival (p=0.55). Older age was strongly associated with poorer OS (hazard ratio 1.34, p<0.0001). Age at diagnosis was the only predictor of survival for recurrent GBM patients. After adjusting for age at diagnosis, multiple resections were not an independent predictor of OS in our glioblastoma cohort treated in the temozolomide era.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Glioblastoma; Multiple resections; Overall survival; Recurrence

Mesh:

Substances:

Year:  2015        PMID: 26671314     DOI: 10.1016/j.jocn.2015.05.047

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  13 in total

1.  Early imaging marker of progressing glioblastoma: a window of opportunity.

Authors:  Na Tosha N Gatson; Shane P Bross; Yazmin Odia; Gino J Mongelluzzo; Yirui Hu; Laura Lockard; Jesse J Manikowski; Anand Mahadevan; Syed A J Kazmi; Michel Lacroix; Andrew R Conger; Joseph Vadakara; Lakshmi Nayak; T Linda Chi; Minesh P Mehta; Vinay K Puduvalli
Journal:  J Neurooncol       Date:  2020-06-29       Impact factor: 4.130

2.  Outcomes after second surgery for recurrent glioblastoma: a retrospective case-control study.

Authors:  Alysson Wann; Patrick A Tully; Elizabeth H Barnes; Zarnie Lwin; Rosalind Jeffree; Katharine J Drummond; Hui Gan; Mustafa Khasraw
Journal:  J Neurooncol       Date:  2018-01-02       Impact factor: 4.130

3.  Assessing the efficacy of repeat resections in recurrent glioblastoma: a systematic review.

Authors:  David Botros; Hayden Dux; Carrie Price; Adham M Khalafallah; Debraj Mukherjee
Journal:  Neurosurg Rev       Date:  2020-06-13       Impact factor: 3.042

4.  Overexpression of p53 delivered using recombinant NDV induces apoptosis in glioma cells by regulating the apoptotic signaling pathway.

Authors:  Xiaoyong Fan; Hongzhen Lu; Youqiang Cui; Xianzeng Hou; Chuanjiang Huang; Guangcun Liu
Journal:  Exp Ther Med       Date:  2018-03-08       Impact factor: 2.447

5.  Impact of recurrence pattern in patients undergoing a second surgery for recurrent glioblastoma.

Authors:  Francesco Pasqualetti; Nicola Montemurro; Isacco Desideri; Mauro Loi; Noemi Giannini; Giovanni Gadducci; Giulia Malfatti; Martina Cantarella; Alessandra Gonnelli; Sabrina Montrone; Luca Visani; Cristian Scatena; Antonio Giuseppe Naccarato; Paolo Perrini; Carlo Gambacciani; Orazio Santonocito; Riccardo Morganti; Fabiola Paiar
Journal:  Acta Neurol Belg       Date:  2021-08-16       Impact factor: 2.396

6.  Impacts of genotypic variants on survival following reoperation for recurrent glioblastoma.

Authors:  Antonio Dono; Ping Zhu; Emma Holmes; Takeshi Takayasu; Jay-Jiguang Zhu; Angel I Blanco; Sigmund Hsu; Meenakshi B Bhattacharjee; Leomar Y Ballester; Dong H Kim; Yoshua Esquenazi; Nitin Tandon
Journal:  J Neurooncol       Date:  2022-01-08       Impact factor: 4.506

7.  Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC.

Authors:  Timothy F Cloughesy; Joseph Landolfi; Michael A Vogelbaum; Derek Ostertag; James B Elder; Stephen Bloomfield; Bob Carter; Clark C Chen; Steven N Kalkanis; Santosh Kesari; Albert Lai; Ian Y Lee; Linda M Liau; Tom Mikkelsen; Phioanh Nghiemphu; David Piccioni; William Accomando; Oscar R Diago; Daniel J Hogan; Dawn Gammon; Noriyuki Kasahara; Thian Kheoh; Douglas J Jolly; Harry E Gruber; Asha Das; Tobias Walbert
Journal:  Neuro Oncol       Date:  2018-09-03       Impact factor: 12.300

8.  Long non-coding RNA MEG3 promotes the proliferation of glioma cells through targeting Wnt/β-catenin signal pathway.

Authors:  X Gong; M Huang
Journal:  Cancer Gene Ther       Date:  2017-10-13       Impact factor: 5.987

9.  Biochanin A Inhibits Glioblastoma Growth via Restricting Glycolysis and Mitochondrial Oxidative Phosphorylation.

Authors:  Qiang Dong; Qiao Li; Lei Duan; Hang Yin; Xiaoqing Wang; Yang Liu; Bo Wang; Kun Li; Xuan Yao; Guoqiang Yuan; Yawen Pan
Journal:  Front Oncol       Date:  2021-07-08       Impact factor: 6.244

10.  Cytotoxic lanthanum oxide nanoparticles sensitize glioblastoma cells to radiation therapy and temozolomide: an in vitro rationale for translational studies.

Authors:  Victor M Lu; Toni Rose Jue; Kerrie L McDonald
Journal:  Sci Rep       Date:  2020-10-23       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.